What the FDA labels say about taking them together
Clarithromycin and lurasidone
Clarithromycin's FDA label of April 9, 2026 names lurasidone in its contraindications section, and lurasidone's label names clarithromycin too. The lurasidone label: “Concomitant use of LATUDA with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone.”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the lurasidone FDA label on DailyMed (effective January 31, 2025, Sumitomo Pharma America, Inc.).
What does the clarithromycin label say about lurasidone?
Clarithromycin label, contraindicationsCONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride and pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone
Clarithromycin label, drug interactionsLurasidone Lurasidone: [See Contraindications (4.7) ] Antispasmodics: Tolterodine (patients deficient in CYP2D6 activity) Use With Caution Tolterodine:
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the lurasidone label say about clarithromycin?
Lurasidone label, contraindicationsStrong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions ( 7.1 )].
Lurasidone label, drug interactionsStrong CYP3A4 Inhibitors Clinical Impact: Concomitant use of LATUDA with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone. Intervention: LATUDA should not be used concomitantly with strong CYP3A4 inhibitors [see Contraindications ()]. Examples: Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil
Source: FDA drug label (Latuda), NDA200603 (Sunovion Pharms Inc), as published by Sumitomo Pharma America, Inc., effective January 31, 2025 (SPL set afad3051-9df2-4c54-9684-e8262a133af8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Lurasidone | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | Schizophrenia, Bipolar disorder, Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | $0.142 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once